Breast and prostate cancer: more similar than different

被引：202

作者：

Risbridger, Gail P. ^{[1
]}

Davis, Ian D. ^{[2
]}

Birrell, Stephen N. ^{[3
]}

Tilley, Wayne D. ^{[3
]}

机构：

[1] Monash Univ, Dept Anat & Dev Biol, Breast & Prostate Canc Res Program, Melbourne, Vic 3800, Australia

[2] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia

[3] Univ Adelaide, Hanson Inst, Dame Roma Mitchell Canc Res Labs, Adelaide, SA 5000, Australia

来源：

NATURE REVIEWS CANCER | 2010年 / 10卷 / 03期

基金：

英国医学研究理事会;

关键词：

ESTROGEN-RECEPTOR-BETA; ANDROGEN-DEPRIVATION THERAPY; TAMOXIFEN RESISTANCE; POSTMENOPAUSAL WOMEN; ABIRATERONE ACETATE; INTRAEPITHELIAL NEOPLASIA; ANTIANDROGEN WITHDRAWAL; SYNTHETIC PROGESTINS; EPITHELIAL GROWTH; ADJUVANT THERAPY;

D O I：

10.1038/nrc2795

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer and prostate cancer are the two most common invasive cancers in women and men, respectively. Although these cancers arise in organs that are different in terms of anatomy and physiological function both organs require gonadal steroids for their development, and tumours that arise from them are typically hormone-dependent and have remarkable underlying biological similarities. Many of the recent advances in understanding the pathophysiology of breast and prostate cancers have paved the way for new treatment strategies. In this Opinion article we discuss some key issues common to breast and prostate cancer and how new insights into these cancers could improve patient outcomes.

引用

页码：205 / 212

页数：8

共 128 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations [J].

Agalliu, Ilir ;

Gern, Robert ;

Leanza, Suzanne ;

Burk, Robert D. .

CLINICAL CANCER RESEARCH, 2009, 15 (03) :1112-1120

[3] CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer [J].

Ang, Je ;

Olmos, D. ;

de Bono, J. S. .

BRITISH JOURNAL OF CANCER, 2009, 100 (05) :671-675

[4]

[Anonymous], BREAST CANC RES

[5] Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? [J].

Antonarakis, Emmanuel S. ;

Eisenberger, Mario A. .

NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01) :12-13

[6] AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].

Anzick, SL ;

Kononen, J ;

Walker, RL ;

Azorsa, DO ;

Tanner, MM ;

Guan, XY ;

Sauter, G ;

Kallioniemi, OP ;

Trent, JM ;

Meltzer, PS .

SCIENCE, 1997, 277 (5328) :965-968

[7] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[8] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[9]

Ayala G, 2003, CLIN CANCER RES, V9, P4792

[10]

Baum M., 2003, CANCER, V98, P1802, DOI DOI 10.1002/CNCR.11745

← 1 2 3 4 5 6 7 8 9 10 →